Physician profile
Dmitriy Zamarin
NPI 1891955357
$13,330.00
in general payments reported to CMS, 2019-2025
10 companies · $2,460 in 2025
The $2,460 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,175 · 2022: $1,200 · 2024: $7,495 · 2025: $2,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,955.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,840.00 | 2024-2025 | |
| Astrazeneca Uk Limited | $2,740.00 | 2024 | |
| Glaxosmithkline, LLC. | $2,175.00 | 2021 | |
| Daiichi Sankyo INC. | $1,875.00 | 2024 | |
| Verastem, INC. | $1,500.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,200.00 | 2022 |
4 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Zamarin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.